Hangzhou Gongshu District Industrial Investment

AstraZeneca partnered with Gongshu District to anchor the life and health industrial cluster inside the Hangzhou Life Health Valley, a flagship industrial park developed by the firm. The collaboration, disclosed in municipal partnership records, positions AstraZeneca as a strategic tenant and innovation partner, giving the district vehicle direct access to pharma-driven venture pipelines that typical district-level funds lack.

The firm acts primarily as a direct investor and industrial developer, not a fund-of-funds allocator. Its structure combines physical park development with venture-stage co-investments, including the RMB 80 million Gongshu Danlu Talent Fund alongside Guangzhou Danlu Equity Investment Management. The firm controls the land, builds the facilities, and seeds companies inside its own industrial estates.

Sourcing runs through the district's industrial park ecosystem. By developing life-science and advanced-manufacturing parks and recruiting anchor tenants like AstraZeneca and Huadong Medicine, the firm creates a captive pipeline of startups, supply-chain vendors, and spin-out ventures that locate inside its controlled real estate. This vertically integrated model differs from open-market fund deployment.

The firm targets life sciences and healthcare, advanced manufacturing, and the digital economy. Confirmed physical assets include a biomanufacturing innovation center for Huadong Medicine, a digital-intelligence future city cluster, and a dedicated life-health valley that houses AstraZeneca's Hangzhou innovation hub.

Total AUM and aggregate deployment are not publicly disclosed. The firm manages at least two named vehicles — the Gongshu District Industrial Fund and the Gongshu Science and Technology Talents Fund — alongside multiple industrial parks valued on the district's balance sheet. An RMB 80 million co-investment vehicle with Guangzhou Danlu Equity Investment Management represents the only publicly sized fund commitment.